Preliminary study on deoxyribonucleic acid methylation of breast cancer anti-resistance 1, phospho-diesterase 1C, opioid receptor delta 1 and neurexin 1 in gout and hyperuricemia
10.3760/cma.j.cn141217-20190617-00222
- VernacularTitle:BCAR1 PDE1C OPRD1 NRXN1启动子区甲基化水平在痛风和高尿酸血症中的初步研究
- Author:
Yong CHEN
1
;
Xiaoke LI
;
Ying YING
;
Yuhan WU
;
Rongxin ZOU
;
Zanbo CHU
;
Yingzi PAN
Author Information
1. 中国科学院大学宁波华美医院风湿免疫科 315000
- From:
Chinese Journal of Rheumatology
2020;24(10):676-680
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To provide a preliminary theoretical basis for gout and hyperuricemia of Deoxyribonucleic acid (DNA) methylation.Methods:Breast cancer anti-resistance 1(BCAR1), phospho-diesterase 1C (PDE1C), opioid receptor delta 1(OPRD1) and neurexin 1(NRXN1) methylation levels were measured by bisulfite pyrosequencing in 50 gout patients, 30 hyperuricemia patients and 50 matched healthy controls. Comparisons between groups were evaluated by F-test and Nonparametric tests. Results:Receiver operating characteristic showed that the methylation of PDE1C(pos4, pos5, pos6)(AUC: 0.712, 0.772, 0.775; all P values<0.05) had higher accuracy for diagnosis of gout, and OPRD1 pos4 (AUC=0.733, P<0.05) had higher accuracy for hyperuricemia. Conclusion:DNA methylation may play a role in the development of gout and hyperuricemia, however, further studies are needed.
